Inactive Instrument

DUCAT VENTURES Stock London S.E.

Equities

Biotechnology & Medical Research

End-of-day quote London S.E.
- GBX - Intraday chart for DUCAT VENTURES
Sales 2021 2.21M 2.73M Sales 2022 457K 564K Capitalization 12.08M 14.9M
Net income 2021 6M 7.4M Net income 2022 2M 2.47M EV / Sales 2021 17.7 x
Net cash position 2021 1.19M 1.47M Net cash position 2022 1.05M 1.3M EV / Sales 2022 24.1 x
P/E ratio 2021
7.02 x
P/E ratio 2022
4.77 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 87.46%
More Fundamentals * Assessed data
Managers TitleAgeSince
Founder 64 06-06-18
Director of Finance/CFO 61 Nov. 30
Director/Board Member - 14-11-17
Members of the board TitleAgeSince
Chairman 72 17-12-31
Director/Board Member 66 18-09-09
Founder 64 06-06-18
More insiders
OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiome, SlimBiome Medical and WellBiome.
More about the company